P6487
Anti-Purinergic Receptor P2Y1 antibody produced in rabbit
affinity isolated antibody, lyophilized powder
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
A propos de cet article
NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
polyclonal
Application:
IHC, WB
Citations:
7
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderService technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderbiological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
lyophilized powder
species reactivity
human, rat
technique(s)
immunohistochemistry: suitable, western blot: suitable
UniProt accession no.
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... P2RY1(5028)
rat ... P2ry1(25265)
General description
Purinergic Receptor P2Y1 is a member of G protein-coupled receptors. The P2Y1 gene is mapped to human chromosome 3q25.2. It is present in the heart, blood vessels, prostate, testis, ovary, and neural tissue.
Immunogen
synthetic peptide corresponding to residues 242-258 of rat or human P2Y1.
Application
Anti-Purinergic Receptor P2Y1 antibody produced in rabbit has been used in western blotting1:200 and immunohistochemistry at a dilution of 1:50.
Biochem/physiol Actions
Purinergic Receptor P2Y1 acts as a receptor for extracellular ATP and ADP. It is essential for ADP-induced platelet activation, aggregation, and thrombosis. P2Y1 also participates in endothelial cell-based nucleotide-induced relaxation and in calcium mobilization. It serves as a potential target for the generation of new antiplatelet compounds and anti-inflammatory strategies.
Physical form
Lyophilized from phosphate buffered saline, pH 7.4, 1% bovine serum albumin and 0.05% sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Milka Koupenova et al.
Frontiers in pharmacology, 9, 37-37 (2018-02-15)
Platelets are small anucleated cells present only in mammals. Platelets mediate intravascular hemostatic balance, prevent interstitial bleeding, and have a major role in thrombosis. Activation of platelet purinergic receptors is instrumental in initiation of hemostasis and formation of the hemostatic
Shara Khan et al.
Diabetologia, 57(12), 2535-2545 (2014-09-12)
There is evidence that ATP acts as an autocrine signal in beta cells but the receptors and pathways involved are incompletely understood. Here we investigate the receptor subtype(s) and mechanism(s) mediating the effects of ATP on human beta cells. We
J Simon et al.
Acta biologica Hungarica, 54(2), 191-201 (2003-10-11)
Since the first identification of P2Y receptor sequences in 1993, it has quickly become apparent that this family of the G-protein coupled receptors is very diverse. Members of this receptor family are activated extra-cellularly by a wide variety of adenosine
Béatrice Hechler et al.
Purinergic signalling, 7(3), 293-303 (2011-07-28)
Following vessel wall injury, platelets adhere to the exposed subendothelium, become activated and release mediators such as TXA(2) and nucleotides stored at very high concentration in the so-called dense granules. Released nucleotides and other soluble agents act in a positive
Agnete Kirkeby et al.
Thrombosis and haemostasis, 99(4), 720-728 (2008-04-09)
The haematopoietic hormone erythropoietin (EPO) has neuroprotective properties and is currently being explored for treatment of stroke and other neurological disorders. Short-term, high-dose treatment with EPO seems to improve neurological function of stroke patients but may be associated with increased
Contenu apparenté
Datasheet
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique